Rabbit Polyclonal FUOM Antibody

The FUOM antibody, an acronym for **Fc-engineered Universal Opsonizing Monoclonal antibody**, emerged from efforts to enhance therapeutic antibodies' efficacy in targeting pathogens or diseased cells. Traditional monoclonal antibodies (mAbs) often rely on specific antigen recognition and immune cell engagement (e.g., phagocytosis, ADCC) via Fc region interactions. However, limitations like antigen diversity, immune evasion, and variable Fc-receptor affinity hindered broad applicability. FUOM antibodies address this by integrating engineered Fc domains optimized for universal opsonization—boosting binding to Fcγ receptors (FcγR) on immune cells across diverse targets. This Fc modification leverages structure-guided mutagenesis or glycoengineering to amplify effector functions, enabling stronger immune cell activation regardless of antigen specificity. Initially explored in oncology to target heterogeneous tumors, FUOM technology has expanded into infectious diseases (e.g., multi-pathogen opsonization) and autoimmune disorders. Preclinical studies highlight enhanced phagocytic clearance of cancer cells and pathogens, with potential for reduced dosing and improved therapeutic windows. Current research focuses on balancing hyperactive Fc signaling to avoid cytokine storms or off-target toxicity. FUOM antibodies represent a promising shift toward "universal" mAb platforms, marrying target flexibility with potent immune modulation.